Market Overview

Rodman & Renshaw Outperform on NuVasive


Rodman & Renshaw is out with a research report on NuVasive, Inc (NASDAQ: NUVA) and it has an Outperform rating and a $33 price target.

In a note to clients, Rodman & Renshaw writes, " The announcement, in our opinion, will have more of a psychological impact on NUVA stock rather than a shift in fundamentals. Reason being – the company's constant drumbeat of “offensive and defensive” strategies seems to have fallen flat.

While this might be farfetched, maybe it's time for NUVA to consider selling itself. Reason being – 1) the luster from the spine surgery space is coming off, 2) competition, especially with more percutaneous technologies including expandable cages could gradually reshape the landscape, 3) Growth will likely slow down over time given pending changes in Medicare & Medicaid, and 4) the law of diminishing returns probably would suggest that it's better to get out now than wait for a rainy day."

Shares of NUVA are off $1.70 to $19.51, a loss of 8.02%.

Posted-In: Rodman & RenshawAnalyst Color Price Target Analyst Ratings


Related Articles (NUVA)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Holy Toledo! Ohio IHOPs Raided By FBI

CRUDE OIL: Bearish Below Its Falling Trendline Resistance (Commodity Technical Outlook).